RVL Pharmaceuticals plc
RVLPQ
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 36.92M | 37.11M | 49.72M | 42.77M | 34.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.92M | 37.11M | 49.72M | 42.77M | 34.95M |
| Cost of Revenue | 6.53M | 6.81M | 6.66M | 7.48M | 6.10M |
| Gross Profit | 30.39M | 30.30M | 43.07M | 35.30M | 28.85M |
| SG&A Expenses | 67.06M | 71.44M | 79.08M | 83.70M | 89.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 76.69M | 81.98M | 89.70M | 95.37M | 99.79M |
| Operating Income | -39.77M | -44.88M | -39.98M | -52.60M | -64.85M |
| Income Before Tax | -68.54M | -56.37M | -51.71M | -52.88M | -64.52M |
| Income Tax Expenses | -277.00K | 113.00K | -20.00K | 165.00K | 426.00K |
| Earnings from Continuing Operations | -68.27 | -56.48 | -51.69 | -53.05 | -64.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -46.00K | 8.44M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.27M | -56.48M | -51.69M | -53.10M | -56.51M |
| EBIT | -39.77M | -44.88M | -39.98M | -52.60M | -64.85M |
| EBITDA | -39.39M | -44.50M | -39.61M | -52.22M | -64.41M |
| EPS Basic | -0.70 | -0.60 | -0.57 | -0.63 | -0.75 |
| Normalized Basic EPS | -0.23 | -0.27 | -0.29 | -0.42 | -0.55 |
| EPS Diluted | -0.70 | -0.60 | -0.57 | -0.63 | -0.75 |
| Normalized Diluted EPS | -0.23 | -0.27 | -0.29 | -0.42 | -0.55 |
| Average Basic Shares Outstanding | 390.61M | 374.82M | 358.98M | 340.70M | 310.89M |
| Average Diluted Shares Outstanding | 390.61M | 374.82M | 358.98M | 340.70M | 310.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |